Serina Therapeutics: Director Departs, CMO Appointed
Ticker: SER · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $450,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-election
TL;DR
Serina Therapeutics shuffles board and execs: Dr. Smith out as director, in as CMO.
AI Summary
Serina Therapeutics, Inc. announced on September 8, 2024, the departure of Director Dr. David E. Smith and the appointment of Dr. David E. Smith as Chief Medical Officer. The company also elected Dr. David E. Smith to its Board of Directors. These changes are effective as of September 8, 2024.
Why It Matters
The appointment of a Chief Medical Officer and the election of a director can signal strategic shifts in leadership and focus for a biotechnology company.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- Dr. David E. Smith (person) — Director and Chief Medical Officer
FAQ
What was the effective date of Dr. David E. Smith's departure as a director and his appointment as Chief Medical Officer?
The effective date for both events was September 8, 2024.
What is Serina Therapeutics, Inc.'s primary business?
Serina Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the principal executive office address for Serina Therapeutics, Inc.?
The principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What other roles does Dr. David E. Smith hold within Serina Therapeutics, Inc. as of September 8, 2024?
As of September 8, 2024, Dr. David E. Smith was appointed Chief Medical Officer and elected to the Board of Directors.
What was Serina Therapeutics, Inc.'s former company name?
Serina Therapeutics, Inc.'s former company name was AgeX Therapeutics, Inc., with a name change date of June 6, 2017.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-09-12 17:17:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
- $450,000 — t provides for an annual base salary of $450,000 and an annual incentive compensation op
- $500,000 — e salary will automatically increase to $500,000 annually, and he will receive a one-tim
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 68KB
- 0001493152-24-036080.txt ( ) — 303KB
- ser-20240908.xsd (EX-101.SCH) — 3KB
- ser-20240908_lab.xml (EX-101.LAB) — 34KB
- ser-20240908_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: September 12, 2024 By: /s/ Steve Ledger Chief Executive Officer